1. Overview: Prostate Cancer Vaccines
1.1. Introduction
1.2. Prostate Cancer Vaccines Types
1.3. Prostate Cancer Vaccines Types - Pros and Cons
1.4. How Cancer Vaccines Works??
1.5. Timeline
1.6. Guidelines in 7MM

2. Market Dynamics: Prostate Cancer Vaccines
2.1. Market Drivers
2.2. Market Barriers
2.3. Market Opportunities

3. CI Analysis: Prostate Cancer Vaccine
3.1. SWOT Analysis

4. Market Scenario: Prostate Cancer Vaccines
4.1 Cancer Vaccine Market Landscape
4.2 FDA Approved Cancer Vaccine
4.2.1 Dendreon Corporation

5. Emerging Companies: Prostate Cancer Vaccines
5.1 Emerging Prostate Cancer Vaccine
5.1.1. Therapeutics Analysis
5.1.2. Late Stage Products (Phase III)
5.1.2.1 Bavarian Nordic
5.1.2.2 Advantagene Inc.
5.1.3 Mid-stage Products (Phase II)
5.1.3.1 OncBioMune Pharmaceuticals
5.1.3.2 Advaxis Immunotherapies
5.1.3.3 Sotio A.S.
5.1.3.4 Cleveland Biolabs
5.1.3.5 CureVac AG
5.1.3.6 Laboratoires Leurquin Mediolanum
5.1.4 Early-Stage Products (Phase I)
5.1.4.1 Pfizer Inc.
5.1.4.2 Vaccitech
5.1.4.3 Sensei Biotherapeutics
5.1.4.4 Medigene AG
5.1.4.5 Ultimovacs
5.1.4.6 Oncovir, Inc
5.1.4.7 UbiVac
5.1.5 Technology-Based Companies
5.1.5.1 Momotaro-Gene Inc
5.1.5.2 Vaccibody
5.1.5.3 AlphaVax, Inc.
5.1.6 Therapeutic Assessment: Clinical Products
5.1.6.1 Assessment by Stage
5.1.6.2 Assessment by Target
5.1.6.3 Assessment by Stage and Target
5.1.6.4 Assessment by Mode of Administration
5.1.6.5 Assessment by Stage and MOA
5.1.6.6 Assessment by Route of Administration
5.1.6.7 Assessment by Stage and ROA

6. Patent Scenario: Prostate Cancer Vaccines
6.1. Patent Overview
6.1.1. Bioimagene, Inc.
6.1.2. The University Of Chicago
6.1.3. University Technology Corporation
6.1.4. Board of Regents, The University of Texas System
6.1.5. Corixa Corporation
6.2. Patent Analysis
Appendix
Report Methodology
Consulting Services
Disclaimer
About DelveInsight
Note: Certain sections of the table of contents would vary according to the availability of information

List of Tables

Table 1: Total Products for Prostate Cancer Vaccine by Phase and Company
Table 2: Total Active Vaccines for Prostate Cancer by Phase
Table 3: Late Stage Products (Phase III)
Table 4: Clinical Trials Description: Bavarian Nordic
Table 5: Product Description: PROSTVAC 41
Table 6: Clinical Trial Description: Advantagene
Table 7: Product Description: ProstAtak
Table 8: Mid Stage Products (Phase II)
Table 9: Clinical Trials Description: OncBioMune Pharmaceuticals
Table 10: Product Description: ProscaVax
Table 11: Clinical Trials Description: Advaxis Immunotherapies
Table 12: Product Description: ADXS-PSA
Table 13: Clinical Trial Description: Sotio
Table 14: Product Description: DCVAC/PCa
Table 15: Clinical Trials Description: Cleveland BioLabs
Table 16: Product Description:M-VM3
Table 17: Clinical Trial Description: Curevac
Table 18: Product Description: CV9103
Table 19: Product Description: CV9104
Table 20 Clinical Trial Description: Laboratoires Leurquin Mediolanum
Table 21: Product Description: GX301
Table 22: Clinical Trials Description: Pfizer
Table 23: Product Description: PF-06753512
Table 24: Clinical Trials Description: Vaccitech
Table 25: Product Description: VTP-800
Table 26: Clinical Trials Description: Sensei Biotherapeutics
Table 27: Product Description: SNS-301
Table 28: Clinical Trials Description: Medigene
Table 29: Product Description : DC vaccine TCR-IIT
Table 30: Clinical Trial Description: Ultimovacs
Table 31: Product Description: UV1 synthetic peptide vaccine
Table 32: Clinical Trial Description: Oncovir
Table 33: Product Description: Hiltonol (PolyICLC)
Table 34: Clinical Trial Description: UbiVac
Table 35: Product Description: DRibble Vaccine DPV-001
Table 36: Assessment by Stage
Table 37:Assessment by MOA
Table 38: Assessment by Stage and MOA
Table 39:Assessment by Route of Administration for Prostate Cancer vaccine
Table 40: Assessment by Stage and Route of Administration
Table 41: Patent
Table 42: Top Inventors In Prostate Vaccine

List of FiguresFigure 1: Characteristics of Normal cell and Cancerous Cell
Figure 2: Cancer Vaccine Immunotherapy
Figure 3: Diagrammatic representation of Normal and Cancerous Prostate
Figure 4: Pros and Cons of different types of cancer vaccines
Figure 5: Mechanism of action of cancer vaccines
Figure 6: Market Drivers
Figure 7: Market Barriers
Figure 8: Market Opportunities
Figure 9: SWOT Analysis
Figure 10: Cancer Vaccine Market
Figure 11: Provenge (sipuleucel-T) Mechanism of Action
Figure 12: Pipeline Therapeutics for Prostate Cancer Vaccine- Total Active Products by Companies
Figure 13: Pipeline Therapeutics for Prostate Cancer Vaccine - Total Active Products by Stage and Companies
Figure 14: Total Active Prostate Cancer Vaccine by Phase
Figure 15: Late Stage Products (Phase III)
Figure 16: Mechanism of action of ProstAtak
Figure 17: Mid Stage Products (Phase II)
Figure 18: Early Stage Products
Figure 19: Mechanism of action of UV1 synthetic peptide vaccine
Figure 20: Mechanism of action of REIC formulation
Figure 21: Vaccibody Vaccine Technology Platform
Figure 22: Alphavaccines Technology Platform
Figure 23: Assessment by Stage
Figure 24: Assessment by Target
Figure 25: Assessment by Stage and Target
Figure 26: Assessment by MOA
Figure 27: Assessment by Stage and MOA
Figure 28: Assessment by Stage and Route of Administration

List Of Companies
• Dendreon Corporation
• Bavarian Nordic
• Advantagene
• OncBioMune Pharmaceuticals
• Advaxis immunotherapies
• SOTIO
• Cleveland BioLabs Inc.
• Curevac AG
• Mediolanum Farmaceutici
• Pfizer Inc.
• Vaccitech
• Sensei Biotherapeutics
• Medigene AG
• Ultimovacs
• Oncovir Inc.
• UbiVac
• Momotaro-Gene Inc.
• Vaccibody AS
• AlphaVax Inc.